Does the media favor MDXG or RNA?

In the previous week, MiMedx Group had 1 more articles in the media than Avidity Biosciences. MarketBeat recorded 3 mentions for MiMedx Group and 2 mentions for Avidity Biosciences. Avidity Biosciences' average media sentiment score of 1.79 beat MiMedx Group's score of 0.60 indicating that Avidity Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MiMedx Group 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Avidity Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Is STTK or RNA more profitable?

Avidity Biosciences' return on equity of 0.00% beat Shattuck Labs' return on equity. Company Net Margins Return on Equity Return on Assets Shattuck Labs N/A -46.46% -43.56% Avidity Biosciences N/A N/A N/A

Does the media refer more to STTK or RNA?

In the previous week, Shattuck Labs had 8 more articles in the media than Avidity Biosciences. MarketBeat recorded 10 mentions for Shattuck Labs and 2 mentions for Avidity Biosciences. Avidity Biosciences' average media sentiment score of 1.79 beat Shattuck Labs' score of -0.33 indicating that Avidity Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Shattuck Labs 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Avidity Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to ACRS or RNA?

In the previous week, Aclaris Therapeutics had 3 more articles in the media than Avidity Biosciences. MarketBeat recorded 5 mentions for Aclaris Therapeutics and 2 mentions for Avidity Biosciences. Avidity Biosciences' average media sentiment score of 1.79 beat Aclaris Therapeutics' score of 0.80 indicating that Avidity Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aclaris Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Avidity Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to RNA or PBYI?

In the previous week, Puma Biotechnology had 8 more articles in the media than Avidity Biosciences. MarketBeat recorded 10 mentions for Puma Biotechnology and 2 mentions for Avidity Biosciences. Avidity Biosciences' average media sentiment score of 1.79 beat Puma Biotechnology's score of 0.65 indicating that Avidity Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avidity Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Puma Biotechnology 0 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Is ENTX or RNA more profitable?

Avidity Biosciences' return on equity of 0.00% beat Entera Bio's return on equity. Company Net Margins Return on Equity Return on Assets Entera Bio N/A -38.55% -36.15% Avidity Biosciences N/A N/A N/A

Does the media refer more to ENTX or RNA?

In the previous week, Entera Bio had 5 more articles in the media than Avidity Biosciences. MarketBeat recorded 7 mentions for Entera Bio and 2 mentions for Avidity Biosciences. Avidity Biosciences' average media sentiment score of 1.79 beat Entera Bio's score of 0.00 indicating that Avidity Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Entera Bio 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Avidity Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Avidity Biosciences (RNA) Competitors

$7.96 -0.27 (-3.28%)

As of 04:00 PM Eastern

Compare

RNA vs. MDXG, STTK, ACRS, PBYI, and ENTX

Should you buy Avidity Biosciences stock or one of its competitors? Avidity Biosciences's main competitors and comparable companies include MiMedx Group (MDXG), Shattuck Labs (STTK), Aclaris Therapeutics (ACRS), Puma Biotechnology (PBYI), and Entera Bio (ENTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Avidity Biosciences compare to MiMedx Group?

MiMedx Group (NASDAQ:MDXG) and Avidity Biosciences (NASDAQ:RNA) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, risk, profitability, dividends, media sentiment and valuation.

MiMedx Group has higher revenue and earnings than Avidity Biosciences. MiMedx Group is trading at a lower price-to-earnings ratio than Avidity Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiMedx Group	$418.63M	1.17	$48.58M	-$0.13	N/A
Avidity Biosciences	N/A	N/A	N/A	-$2.15	N/A

Avidity Biosciences has a net margin of 0.00% compared to MiMedx Group's net margin of -6.32%. MiMedx Group's return on equity of 2.39% beat Avidity Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiMedx Group	-6.32%	2.39%	1.85%
Avidity Biosciences	N/A	N/A	N/A

In the previous week, MiMedx Group had 1 more articles in the media than Avidity Biosciences. MarketBeat recorded 3 mentions for MiMedx Group and 2 mentions for Avidity Biosciences. Avidity Biosciences' average media sentiment score of 1.79 beat MiMedx Group's score of 0.60 indicating that Avidity Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiMedx Group	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Avidity Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

MiMedx Group presently has a consensus price target of $8.14, indicating a potential upside of 141.63%. Avidity Biosciences has a consensus price target of $33.00, indicating a potential upside of 300.97%. Given Avidity Biosciences' higher possible upside, analysts plainly believe Avidity Biosciences is more favorable than MiMedx Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiMedx Group	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Avidity Biosciences	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.56

79.2% of MiMedx Group shares are owned by institutional investors. 2.5% of MiMedx Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

MiMedx Group beats Avidity Biosciences on 9 of the 14 factors compared between the two stocks.

How does Avidity Biosciences compare to Shattuck Labs?

Shattuck Labs (NASDAQ:STTK) and Avidity Biosciences (NASDAQ:RNA) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk, media sentiment and analyst recommendations.

In the previous week, Shattuck Labs had 8 more articles in the media than Avidity Biosciences. MarketBeat recorded 10 mentions for Shattuck Labs and 2 mentions for Avidity Biosciences. Avidity Biosciences' average media sentiment score of 1.79 beat Shattuck Labs' score of -0.33 indicating that Avidity Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Shattuck Labs	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Avidity Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Avidity Biosciences' return on equity of 0.00% beat Shattuck Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shattuck Labs	N/A	-46.46%	-43.56%
Avidity Biosciences	N/A	N/A	N/A

Shattuck Labs presently has a consensus target price of $13.70, indicating a potential upside of 182.47%. Avidity Biosciences has a consensus target price of $33.00, indicating a potential upside of 300.97%. Given Avidity Biosciences' higher possible upside, analysts clearly believe Avidity Biosciences is more favorable than Shattuck Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shattuck Labs	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	3.08
Avidity Biosciences	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.56

Avidity Biosciences has lower revenue, but higher earnings than Shattuck Labs. Shattuck Labs is trading at a lower price-to-earnings ratio than Avidity Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shattuck Labs	$1M	493.92	-$48.81M	-$0.51	N/A
Avidity Biosciences	N/A	N/A	N/A	-$2.15	N/A

58.7% of Shattuck Labs shares are held by institutional investors. 8.8% of Shattuck Labs shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Shattuck Labs beats Avidity Biosciences on 8 of the 13 factors compared between the two stocks.

How does Avidity Biosciences compare to Aclaris Therapeutics?

Aclaris Therapeutics (NASDAQ:ACRS) and Avidity Biosciences (NASDAQ:RNA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, dividends, risk, profitability, valuation and earnings.

98.3% of Aclaris Therapeutics shares are owned by institutional investors. 4.8% of Aclaris Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Aclaris Therapeutics had 3 more articles in the media than Avidity Biosciences. MarketBeat recorded 5 mentions for Aclaris Therapeutics and 2 mentions for Avidity Biosciences. Avidity Biosciences' average media sentiment score of 1.79 beat Aclaris Therapeutics' score of 0.80 indicating that Avidity Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aclaris Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Avidity Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Avidity Biosciences has a net margin of 0.00% compared to Aclaris Therapeutics' net margin of -1,244.09%. Avidity Biosciences' return on equity of 0.00% beat Aclaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aclaris Therapeutics	-1,244.09%	-59.19%	-42.19%
Avidity Biosciences	N/A	N/A	N/A

Avidity Biosciences has lower revenue, but higher earnings than Aclaris Therapeutics. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Avidity Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclaris Therapeutics	$6.40M	90.65	-$64.92M	-$0.58	N/A
Avidity Biosciences	N/A	N/A	N/A	-$2.15	N/A

Aclaris Therapeutics presently has a consensus price target of $11.33, indicating a potential upside of 173.09%. Avidity Biosciences has a consensus price target of $33.00, indicating a potential upside of 300.97%. Given Avidity Biosciences' higher probable upside, analysts clearly believe Avidity Biosciences is more favorable than Aclaris Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	3.11
Avidity Biosciences	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.56

Summary

Aclaris Therapeutics beats Avidity Biosciences on 8 of the 14 factors compared between the two stocks.

How does Avidity Biosciences compare to Puma Biotechnology?

Avidity Biosciences (NASDAQ:RNA) and Puma Biotechnology (NASDAQ:PBYI) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

Avidity Biosciences currently has a consensus target price of $33.00, suggesting a potential upside of 300.97%. Puma Biotechnology has a consensus target price of $6.00, suggesting a potential downside of 26.29%. Given Avidity Biosciences' stronger consensus rating and higher possible upside, research analysts plainly believe Avidity Biosciences is more favorable than Puma Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avidity Biosciences	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.56
Puma Biotechnology	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Puma Biotechnology had 8 more articles in the media than Avidity Biosciences. MarketBeat recorded 10 mentions for Puma Biotechnology and 2 mentions for Avidity Biosciences. Avidity Biosciences' average media sentiment score of 1.79 beat Puma Biotechnology's score of 0.65 indicating that Avidity Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avidity Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Puma Biotechnology	0 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

61.3% of Puma Biotechnology shares are held by institutional investors. 22.2% of Puma Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Puma Biotechnology has higher revenue and earnings than Avidity Biosciences. Avidity Biosciences is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avidity Biosciences	N/A	N/A	N/A	-$2.15	N/A
Puma Biotechnology	$231.83M	1.81	$31.11M	$0.46	17.70

Puma Biotechnology has a net margin of 10.26% compared to Avidity Biosciences' net margin of 0.00%. Puma Biotechnology's return on equity of 17.97% beat Avidity Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avidity Biosciences	N/A	N/A	N/A
Puma Biotechnology	10.26%	17.97%	11.87%

Summary

Puma Biotechnology beats Avidity Biosciences on 9 of the 14 factors compared between the two stocks.

How does Avidity Biosciences compare to Entera Bio?

Entera Bio (NASDAQ:ENTX) and Avidity Biosciences (NASDAQ:RNA) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, valuation, dividends, profitability, earnings, institutional ownership and risk.

Avidity Biosciences' return on equity of 0.00% beat Entera Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entera Bio	N/A	-38.55%	-36.15%
Avidity Biosciences	N/A	N/A	N/A

14.1% of Entera Bio shares are held by institutional investors. 3.7% of Entera Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Entera Bio currently has a consensus price target of $9.60, suggesting a potential upside of 196.30%. Avidity Biosciences has a consensus price target of $33.00, suggesting a potential upside of 300.97%. Given Avidity Biosciences' higher possible upside, analysts plainly believe Avidity Biosciences is more favorable than Entera Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entera Bio	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Avidity Biosciences	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.56

Avidity Biosciences has lower revenue, but higher earnings than Entera Bio. Entera Bio is trading at a lower price-to-earnings ratio than Avidity Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entera Bio	$40K	14,105.34	-$11.44M	-$0.39	N/A
Avidity Biosciences	N/A	N/A	N/A	-$2.15	N/A

In the previous week, Entera Bio had 5 more articles in the media than Avidity Biosciences. MarketBeat recorded 7 mentions for Entera Bio and 2 mentions for Avidity Biosciences. Avidity Biosciences' average media sentiment score of 1.79 beat Entera Bio's score of 0.00 indicating that Avidity Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Entera Bio	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Avidity Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Entera Bio beats Avidity Biosciences on 6 of the 11 factors compared between the two stocks.

Get Avidity Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RNA vs. The Competition

Export

Metric	Avidity Biosciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$136.20M	$4.17B	$7.89B	$12.22B
Dividend Yield	N/A	3.64%	2.47%	4.44%
P/E Ratio	-3.70	25.46	35.35	30.86
Price / Sales	N/A	16.44	8.45	5.83
Price / Cash	N/A	26.87	22.22	22.66
Price / Book	N/A	4.21	4.43	3.79
Net Income	N/A	-$22.76M	$3.50B	$390.16M
7 Day Performance	-8.29%	-1.04%	-0.95%	-1.10%
1 Month Performance	-5.24%	-6.74%	-4.05%	-6.18%
1 Year Performance	-88.74%	1.86%	2.09%	-5.73%

Avidity Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RNA Avidity Biosciences	2.0904 of 5 stars	$7.96 -3.3%	$33.00 +314.6%	-88.2%	$136.20M	N/A	N/A	190	Positive News Upcoming Earnings
MDXG MiMedx Group	2.4392 of 5 stars	$3.28 -15.5%	$8.14 +148.3%	-56.3%	$566.19M	$303.73M	N/A	808
STTK Shattuck Labs	2.0972 of 5 stars	$5.32 -4.3%	$13.70 +157.5%	+156.6%	$558.02M	$1M	N/A	40	Earnings Report Analyst Revision
ACRS Aclaris Therapeutics	3.3715 of 5 stars	$3.80 -4.3%	$11.33 +198.2%	+94.8%	$553.70M	$7.83M	N/A	73	Earnings Report Analyst Revision
PBYI Puma Biotechnology	1.2796 of 5 stars	$10.18 -2.5%	$6.00 -41.1%	+72.1%	$548.21M	$228.40M	19.58	179	Earnings Report Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RNA) was last updated on 11/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Avidity Biosciences (RNA) Competitors

RNA vs. MDXG, STTK, ACRS, PBYI, and ENTX

How does Avidity Biosciences compare to MiMedx Group?

Summary

How does Avidity Biosciences compare to Shattuck Labs?

Summary

How does Avidity Biosciences compare to Aclaris Therapeutics?

Summary

How does Avidity Biosciences compare to Puma Biotechnology?

Summary

How does Avidity Biosciences compare to Entera Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNA vs. The Competition

Avidity Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Avidity Biosciences (RNA) Competitors

RNA vs. MDXG, STTK, ACRS, PBYI, and ENTX

How does Avidity Biosciences compare to MiMedx Group?

Which has stronger valuation and earnings, MDXG or RNA?

Is MDXG or RNA more profitable?

Does the media favor MDXG or RNA?

Do analysts recommend MDXG or RNA?

Do insiders and institutionals have more ownership in MDXG or RNA?

Summary

How does Avidity Biosciences compare to Shattuck Labs?

Does the media refer more to STTK or RNA?

Is STTK or RNA more profitable?

Do analysts recommend STTK or RNA?

Which has better valuation & earnings, STTK or RNA?

Do institutionals & insiders believe in STTK or RNA?

Summary

How does Avidity Biosciences compare to Aclaris Therapeutics?

Do insiders & institutionals have more ownership in ACRS or RNA?

Does the media refer more to ACRS or RNA?

Is ACRS or RNA more profitable?

Which has preferable valuation & earnings, ACRS or RNA?

Do analysts rate ACRS or RNA?

Summary

How does Avidity Biosciences compare to Puma Biotechnology?

Do analysts prefer RNA or PBYI?

Does the media refer more to RNA or PBYI?

Do insiders and institutionals have more ownership in RNA or PBYI?

Which has better earnings & valuation, RNA or PBYI?

Is RNA or PBYI more profitable?

Summary

How does Avidity Biosciences compare to Entera Bio?

Is ENTX or RNA more profitable?

Do institutionals & insiders hold more shares of ENTX or RNA?

Do analysts rate ENTX or RNA?

Which has preferable earnings & valuation, ENTX or RNA?

Does the media refer more to ENTX or RNA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNA vs. The Competition

Avidity Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools